Can a daily spoonful of extra virgin olive oil calm inflammation?
NCT ID NCT07784166
First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time
Summary
This trial asks whether drinking 30 mL of extra virgin olive oil every day for a month can reduce inflammation and blood clotting in healthy adults. About 54 volunteers will be randomly assigned to take either extra virgin olive oil or regular table olive oil. Blood samples taken before and after the month will measure how well platelets respond to clotting triggers, giving clues about the oil's anti-inflammatory and antithrombotic potential.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Extra virgin olive oil (EVOO) consumed daily for 28 days
- What this could lead to
- If it works, this could support using extra virgin olive oil as a natural way to lower inflammation and clotting risk in healthy people.
- What could go wrong
- This is a small, early study in healthy volunteers, so results may not apply to people with health conditions. The effect may be modest and not lead to clear health benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
54 people
The number who actually took part.
- Started
-
Nov 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Not to have a pathological condition related to platelet and leukocyte activity * Not to have a chronic pathological condition * To have a Normal Body Mass Index (BMI) and waist circumference * Not to take medications/supplements or any kind of other intervention that have anti-inflammatory and/or antithrombotic and/or antioxidant effects Exclusion Criteria: * To have a pathological condition related to platelet and leukocyte activity * To have a chronic pathological condition * Not to have a Normal Body Mass Index (BMI) and waist circumference * To take medications/supplements/nutraceuticals or any kind of other intervention that have anti-inflammatory and/or antithrombotic and/or antioxidant effects
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anti-inflammatory agents, non-steroidal are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biochemistry Lab, Hephaestus Laboratory, School of Chemistry, Faculty of Sciences, Kavala University Campus, Democritus University of Thrace
Kavala, 65404, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.